Results 221 to 230 of about 5,574 (244)

PHARMACEUTICALS Merck deal with South Korea’s Hanwha bolsters move into biosimilars

Chemical & Engineering News Archive, 2011
openaire   +1 more source

Economics as a guide to developing public policies for biosimilar pharmaceutical products

Queen Mary Journal of Intellectual Property, 2012
openaire   +1 more source

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Lancet, The, 2019
Beyong Duk Ye, Adi Lahat, Sigal Fishman
exaly  

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions

Lancet Oncology, The, 2020
Charles L Bennett, Shamia Hoque, Bartlett J Witherspoon   +2 more
exaly  

Infliximab biosimilar CT-P13 in Crohn's disease

Lancet, The, 2019
Geert D'Haens
exaly  

Clinical safety of biosimilar recombinant human erythropoietins

Expert Opinion on Drug Safety, 2012
Ivo Abraham
exaly  

Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

Expert Opinion on Drug Safety, 2013
Ivo Abraham
exaly  

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Chemical Reviews, 2016
Yu Zhou, Zhanni Gu, Wei Zhu
exaly  

Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods

Chemical Reviews, 2019
Manvendra Patel, Rahul Kumar, Kamal Kishor   +2 more
exaly  

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

European Journal of Health Economics, 2014
Valentin Brodszky, Petra Baji, Márta Péntek   +2 more
exaly